Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anthelminthic Agents

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Predicting overall survival in synchronous metastatic nasopharyngeal carcinoma using a stacking ensemble machine learning model: a multicenter retrospective study.

Frontiers in oncology·2026

Same author

The Role of Narrative Medicine in Radiation Oncology Education: A Comprehensive Review.

Journal of medical education and curricular development·2026

Same author

Ethanol-Inducible Bioproduction of Human α-Lactalbumin in <i>Komagataella phaffii</i>.

Journal of agricultural and food chemistry·2025

Same author

Synergistic Anticancer Effects of Silibinin and Sulforaphane: Targeting Gastric Cancer via PI3K/AKT and ERK1/2 MAPK Pathway Inhibition and Molecular Docking Insights.

Journal of biochemical and molecular toxicology·2025

Same author

Targeting KMT5C Suppresses Lung Cancer Progression and Enhances the Efficacy of Immunotherapy.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025

Same author

Prognostic value of perioperative NER levels combined with Ca199 in cholangiocarcinoma surgery.

Current problems in surgery·2025

Search research articles

Related Experiment Video

Updated: May 14, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Fenbendazole as a potential anticancer drug.

Qiwen Duan¹, Yanfeng Liu, Sara Rockwell

¹Department of Therapeutic Radiology, Yale University School of Medicine, PO Box 208040, New Haven, CT 06520-8040, USA. sara.rockwell@yale.edu

Anticancer Research

|February 9, 2013

Summary

Fenbendazole, an antihelminth drug, showed no significant anticancer effects alone or with radiation and docetaxel in mouse models. Further investigation into this drug class is suggested for potential cancer therapy applications.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Related Experiment Videos

Last Updated: May 14, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Area of Science:

Pharmacology
Oncology
Drug Discovery

Background:

Fenbendazole is a broad-spectrum antihelminth.
Its mechanism of action shares similarities with hypoxia-selective cytotoxins and taxanes.

Purpose of the Study:

To evaluate the anticancer activity of fenbendazole.
To assess its efficacy as a single agent and in combination therapies.

Main Methods:

In vitro studies using EMT6 mouse mammary tumor cells.
In vivo studies using solid EMT6 tumors in mice.
Combination treatments with radiation and docetaxel were investigated.

Main Results:

Fenbendazole exhibited in vitro toxicity to EMT6 cells, enhanced by incubation time and severe hypoxia.
No synergistic effects were observed when combined with radiation or docetaxel; additive toxicities were noted.
Fenbendazole did not inhibit tumor growth or potentiate radiation's antineoplastic effects in vivo.

Conclusions:

Current evidence does not support fenbendazole's use in cancer therapy.
The broader class of compounds warrants further investigation for potential anticancer applications.